ESR1 and breast carcinoma: This observation is supported by previous studies that identified activating ESR1 mutations in hormone-resistant metastatic breast cancer and linked allele-specific chromatin recruitment to therapeutic resistance mechanisms in ERα mutant breast cancer [31, 42, 43].